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Abstract: Heterogeneity of asthma and difficulty in achieving optimal control are the major 
challenges in the management of asthma. To help attain the best possible clinical outcomes in 
patients with asthma, several guidelines provide recommendations for patients who will require 
a referral to a specialist. Such referrals can help in clearing the uncertainty from the initial 
diagnosis, provide tailored treatment options to patients with persistent symptoms and offer the 
patients access to health care providers with expertise in the management of the asthma; thus, 
specialist referrals have a substantial impact on disease prognosis and the patient’s health status. 
Hurdles in implementing these recommendations include lack of their dissemination among 
health care providers and nonadherence to these guidelines; these hurdles considerably limit the 
implementation of specialist referrals, eventually affecting the rate of referrals. In this review, 
recommendations for specialist referrals from several key international and national asthma 
guidelines and other relevant published literature are evaluated. Furthermore, we highlight why 
referrals are not happening, how this can be improved, and ultimately, what should be done in 
the specialist setting, based on existing evidence in published literature.
Keywords: asthma, disease management, specialization, primary care physicians, referral
Introduction
Asthma is a chronic inflammatory disease of the airway that affects between 235 and 
300 million people worldwide, with ~250,000 annual deaths worldwide attributed to 
this disease.1,2 However, asthma is not a simple airway disease; it is heterogeneous 
and associated with a range of phenotypes related to age of onset, triggers and type of 
inflammation (eosinophilic, neutrophilic and pauci-granulocytic phenotypes), and can 
be further defined on the basis of endotypes.3,4 Furthermore, asthma-related symptoms 
(such as shortness of breath, chest tightness, cough and wheezing that can vary over time 
and in intensity, together with variable expiratory airflow limitation) are shared with 
other conditions such as acute and long-term cardiovascular, metabolic, psychologic/
psychiatric and other respiratory conditions. Owing to the complexity of the disease, 
certain patients with asthma will require a referral to an asthma specialist to address 
certain aspects of their condition. Such a referral can have a significant impact on 
the patient’s health status. Currently, numerous guidelines are available that provide 
guidance on when a patient with asthma should be referred to a specialist. For optimal 
management of these patients, it is important that guideline recommendations for 
specialist referrals are implemented fully and consistently. In this regard, an overview 
of the current practice of specialist referrals, possible hurdles in the implementation of 
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referrals and possible strategies for improved rate of referrals 
would be helpful. This review explores the criteria set forth 
as reasons for referring patients to specialists from various 
guidelines/strategy documents and how these referrals are 
utilized in the management of asthma patients.
Methods for compiling 
asthma guidelines/strategy 
recommendations for specialist 
referral
In order to compile asthma guidelines that would be reviewed, 
a four-step process was utilized. All well-documented inter-
national and national guidelines were obtained (Figure 1). A 
review of the literature was also carried out by searching the 
PubMed database (from 1995 to 2016) using the search term 
“asthma guidelines” and restricting the article type to “guide-
line” (Figure 1). The retrieved publications from this search 
were manually reviewed and nonrelevant publications were 
excluded based on several criteria as outlined in Figure 1. 
The International Primary Care Respiratory Group asthma 
guideline database was also searched for national asthma 
guidelines (Figure 1). Finally, once the asthma guidelines/
consensus documentations were identified by the methods 
previously described, subsequent searches were conducted 
using the Google search engine to establish if updated ver-
sions existed (Figure 1).
For this review, literature searches were restricted to 
guidelines, as previously stated, or manuscripts in English 
language; limited information from regional guidelines 
has also been included due to their international impact 
(e.g., Spanish Guideline on the Management of Asthma 
[GEMA] and the Japanese asthma guidelines). Using the 
common themes from the guidelines/strategy documents 
that specialists can play a pivotal role in all aspects of asthma 
management, all the guidelines/strategy documents criteria/
Figure 1 Guideline selection process.
Abbreviations: AAAAI, American Academy of Allergy Asthma and Immunology; EPR-3, Expert Panel Report-3; GINA, Global Initiative for Asthma; ICON, International 
Consensus; IPCRG, International Primary Care Respiratory Group; NAEPP, National Asthma Education and Prevention Program; PRACTALL, Practical Allergy.
IPCRG
National asthma guidelines
(n=21)
Excluded guidelines that were 
not in English, were currently 
unavailable, recommended 
using alternative guidelines, 
duplicated previous searches, 
or hyperlinks did not work
(n=18)
International and national guidelines
GINA (adult and for children 5 years or younger), NAEPP EPR-3, PRACTALL consensus report, ICON on pediatric
asthma, AAAAI practice parameters for the diagnosis and treatment of asthma and AAAAI consultation and referral guidelines
(n=7)
PubMed
Publications using search term
"asthma guidelines" and article
type "guideline"
(n=379)
Publications between 1995 and
2016 and in English
(n=249)
Excluded publications that were
not asthma guidelines
(n=190)
Publications retrieved
(n=59)
National asthma
guidelines
(n=6)
National asthma
guidelines
(n=3)
Excluded publications that were not a 
national guideline or general asthma 
guideline, were unavailable, erratum, were
out of date guidelines, guidelines based on
GINA, or duplicated from others' searches
(n=53)
Updated and available
guidelines
(n=1)
Google search
Updated versions of guidelines
that were out of date and not
covered in PubMed search
(n=2)
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recommendations for referrals were examined under four 
categories: 1) diagnostic uncertainty, 2) asthma severity and 
high-risk patients, 3) use of corticosteroid treatment (high 
doses, long-term use and side effects) and 4) the use of add-
on specialist therapy (biologics). Tables 1 and 2 summarize 
the results of the compiled guidelines/strategy documents 
(specialist referral recommendations based on guideline and 
evidence) for adults and children, respectively.
Asthma guidelines as sources for 
indications for specialist referrals
Global and national guidelines aim to improve the diagnosis 
and management of asthma and ensure that the best practice 
is implemented consistently. The Global Initiative for Asthma 
(GINA) has developed a detailed recommendation on the 
global strategy for asthma management, but because it is 
only a strategy, the indications for referral may vary due to 
variations across health care systems.5 The GINA strategy is 
designed to be adapted in order to improve its implementation 
within the local health care systems or to increase its use for 
a particular health care professional (HCP).6,7 The national 
guidelines include the British Thoracic Society (BTS) asthma 
guideline in the UK,8 the National Asthma Education and 
Prevention Program (NAEPP) Expert Panel Report-3 in the 
USA,9 GEMA in Spain,10 the Japanese asthma guidelines11 
and the South African guideline.12 Guidelines that address 
asthma management in children include the NAEPP, the 
Practical Allergy (PRACTALL) consensus report, the GINA 
strategy document on asthma management and prevention in 
children aged 5 years and younger5,9,13 and the International 
Consensus on pediatric asthma,14 with some countries, 
such as South Africa and Japan, having specific national 
guidelines.15,16 Adherence to asthma guidelines/strategy 
documents, such as the GINA strategy, has been shown to 
improve the quality of life17 and decrease the morbidity and 
mortality associated with asthma.18
Guideline and strategy documents 
recommendations for specialist 
referrals
Diagnostic uncertainty
Asthma diagnosis could be confounded by a lack of access to 
diagnostic equipment, which is also a reason to seek referral. 
Several of the guidelines confirm an uncertain diagnosis of 
asthma as a reason to refer patients to a specialist, except 
for the PRACTALL consensus report13 and the Japanese 
guideline for children16 (Table 2).
Several factors aid asthma diagnosis, such as a carefully 
recorded history, and clinical and diagnostic assessments 
(spirometry and biomarkers), and all of the guidelines 
presented in Table 1 allude to these to some extent. GINA 
recommends spirometry as the preferred diagnostic test for 
asthma, whereby measurements of airflow limitation, revers-
ibility or bronchial challenge are also used to establish a 
diagnosis of asthma,5 and the involvement of a specialist can 
result in better access to this tool.19 More recently, fractional 
exhaled nitric oxide (FeNO) has been identified as another 
diagnostic tool for establishing an asthma diagnosis;20 how-
ever, depending on the health care system, not all necessary 
tests (e.g., spirometry, FeNO, hyperresponsiveness) may be 
available in primary care facilities, and BTS asthma guideline 
clearly indicates that referral to specialist should be sought 
should such diagnostic tests not be available in primary care.8 
Furthermore, discrepancy between guidelines and strategy 
documents exists on such diagnostics tools. An example of 
this would be the test for FeNO, where GINA states that this 
test has not been established as being useful in making a 
diagnosis of asthma.5 On the other hand, in the recent BTS 
guidelines, a positive FeNO test increases the probability of 
asthma but a negative test does not exclude asthma.8
A recent real-life study demonstrated that using a single 
test alone was not optimal for an accurate diagnosis, but 
rather a combination of multiple diagnostic tests in a spe-
cialist setting resulted in an increase in diagnostic accuracy, 
and determined that 81% of asthma cases could be con-
firmed objectively.21 Diagnostic uncertainty in asthma is 
evident from the literature, as there is conflicting evidence 
on asthma being underdiagnosed22,23 or overdiagnosed,24–26 
suggesting that the correct or accurate diagnosis of asthma, 
especially in children,27 remains an issue among physicians. 
Clinical symptoms of asthma (e.g., cough and wheezing) do 
not definitively confirm an asthma diagnosis, especially in 
children.5,9,13 Also, there is variability among physicians in 
identifying the standard primary symptoms of asthma.28 Inter-
estingly, the GINA strategy for children under 5 years of age 
suggests that several key indications should lead to a refer-
ral for further diagnostic investigations, such as therapeutic 
trials of inhaled medication; testing for atopy; chest X-ray; 
spirometry in children 4–5 years of age; FeNO; and risk pro-
filing tools, for example, asthma predictive index (Table 2).5 
The American Academy of Allergy Asthma and Immunology 
(AAAAI) consultation and referral guidelines also suggest 
that patients with respiratory symptoms who have a normal 
lung function should be referred to an immunologist/allergist 
for a methacholine challenge test.29 For patients with allergic 
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Table 1 Guideline recommendations for referral of adult asthma patients to a specialist
Situations indicated for specialist referral
Guideline Diagnostic uncertainty High-risk patients Corticosteroid treatment 
(high dose, long-term use 
and side effects)
Add-on specialist 
treatment
GINA: global 
strategy for asthma 
management and 
prevention (2016)5
•	 Difficulty in confirming 
the diagnosis of asthma
•	 Patient has symptoms 
of chronic infection 
or features suggesting 
a cardiac or other 
nonpulmonary cause 
(immediate referral 
recommended)
•	 Persistent uncontrolled asthma or 
frequent exacerbations, or low lung 
function despite correct inhaler 
technique and good adherence with 
step 4 treatment (moderate or high-
dose ICS/LABA)
•	 Symptoms suggesting complications 
or subtypes of asthma
•	 Patient has frequent asthma-related 
health care utilization
•	 Any risk factors for asthma-related 
death
•	 Evidence of, or risk of, 
significant treatment side 
effects
•	 Step 5 treatment, referral 
for specialist investigation 
and consideration of add-on 
treatment
•	 Need for long-term OCS 
use
•	 Frequent courses of OCS 
(two or more courses a 
year)
•	 Omalizumab or 
mepolizumab 
treatment for 
patients who are 
uncontrolled at step 
4 (moderate or high-
dose ICS/LABA)
AAAAI practice 
parameters for 
the diagnosis 
and treatment 
of asthma (1995)29
•	 For identification of 
allergens or other 
environmental factors 
that may be causing the 
patients’ disease; patients 
with asthma must have 
access to a thorough 
etiologic evaluation and 
appropriate diagnostics
•	 For all asthmatic patients and, in 
particular, those with asthma that 
is difficult to control, consider a 
referral
•	 Fatality-prone asthmatic patients 
requiring special planning, including 
monitoring of the patient’s course 
with regard to the need
•	 When the patient requires 
multiple medications on a 
long-term basis
•	 When frequent bursts of 
OCS or daily OCS are 
required
•	 When there is a concern 
about the side effects that 
have occurred or may occur
•	 NR
AAAAI 
consultation and 
referral guidelines 
(2011)29
•	 Patients with respiratory 
symptoms suggestive of 
asthma, but with normal 
pulmonary function 
test for a methacholine 
challenge test
•	 Patients with asthma who require ED 
care for acute episode
•	 Uncontrolled asthma
•	 Severe asthma
•	 Persistent asthma, particularly 
moderate-severe persistent asthma
•	 Patients with potentially fatal asthma
•	 Unacceptable side effects of 
medications
•	 Immunomodulator 
therapy (anti-IgE) 
National Asthma 
Council Australia 
(2015)88
•	 Diagnostics tests (FEV1 
pre-/post-bronchodilator, 
reversible airflow 
limitation, FEV1/FVC 
less than the lower 
limit for age, bronchial 
provocation test) do not 
support asthma diagnosis
•	 Poor lung function with 
few symptoms and after a 
3-month trial of high-dose 
ICS
•	 Uncontrolled asthma on ICS/LABA 
combination (moderate to high dose)
•	 Difficult-to-treat asthma
•	 If poor lung function persists with 
a few symptoms after 3 months of 
higher dose ICS
•	 NR •	 NR
British Thoracic 
Society (2016)8
•	 Diagnosis unclear Patients with the following symptoms:
•	 Persistent nonvariable breathlessness;
•	 Monophonic wheeze or stridor;
•	 Prominent systemic features (myalgia, 
fever, weight loss);
•	 Chronic sputum production;
•	 Chest X-ray shadowing;
•	 Marked blood eosinophilia 
(>1×109/L);
•	 Poor response to asthma treatment at 
step 4 prior to proceeding to step 5
•	 Severe asthma attack
•	 Receiving high-does ICS 
should be under specialist 
care
•	 Continuous or frequent use 
of oral steroids
•	 Omalizumab 
treatment in severe 
and difficult allergic 
asthma patients who 
are on high-dose ICS 
and LABA (>6 years 
of age)
(Continued)
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Table 1 (Continued)
Situations indicated for specialist referral
Guideline Diagnostic uncertainty High-risk patients Corticosteroid treatment 
(high dose, long-term use 
and side effects)
Add-on specialist 
treatment
Canadian Thoracic 
Society Guideline 
Update: Diagnosis 
and management 
of asthma in 
preschoolers, 
children and adults 
(2012)50
•	 NR •	 Children (6–12 years of age) who fail 
to achieve control on a medium dose 
of ICS
•	 Uncontrolled asthma in individuals 
>12 years of age who are on an 
ICS/LABA combination
•	 In children and adults, the 
use of high doses of ICS due 
to possible significant side 
effects
•	 In all age groups, frequent 
courses of OCS should 
prompt referral to a 
specialist
•	 Omalizumab 
considered for 
patients >12 years 
of age with asthma 
poorly controlled 
despite high doses of 
ICS and appropriate 
add-on therapy, with 
or without OCS
GEMA (2009)10 •	 NR •	 Patients with difficult-to-control 
asthma should normally be controlled 
at specialized hospital centers by 
experienced medical personnel
•	 When attacks are severe and/or 
complications are suspected, patients 
must be referred to a hospital ED
•	 A history of high-risk attacks
•	 Failure to respond to treatment, 
patients must be referred to a 
hospital ED
•	 NR •	 NR
Ireland asthma 
control in general 
practice (2012)
•	 Diagnosis is in doubt •	 Post-hospitalization, if patient is 
uncontrolled at step 3 (GINA)
•	 NR •	 NR
Japanese guideline 
for adult asthma 
(2011)6
•	 Diagnosis is challenging •	 Patients with underlying 
diseases such as AIA, CSS, other 
systemic vasculitis, and allergic 
bronchopulmonary aspergillosis
•	 Long-term treatment (ICS, 
ICS/LABA, LTRA and omalizumab) 
is challenging
•	 NR •	 Long-term 
treatment with 
omalizumab is 
challenging
NAEPP (2007)9 •	 Signs and symptoms are 
atypical or there are 
problems in differential 
diagnosis
•	 Additional diagnostic 
testing is indicated (e.g., 
allergy skin testing, 
rhinoscopy, complete 
pulmonary function 
studies, provocative 
challenge and 
bronchoscopy)
•	 Other conditions 
complicate diagnosis (e.g., 
sinusitis, nasal polyps, 
aspergillosis, severe 
rhinitis, VCD, GERD and 
COPD)
•	 Patients who had a life-threatening 
asthma exacerbation or 
hospitalization as a result of an 
exacerbation
•	 Patients who have difficulties 
achieving or maintaining control of 
asthma (goals of asthma therapy 
after 3–6 months of treatment) and 
patient is deemed unresponsive to 
treatment by a physician
•	 Patient requires additional education 
and guidance on complications of 
therapy, problems with adherence or 
allergen avoidance
•	 Patient requires step 4 care or higher 
(step 3 for children 0–4 years of age)
•	 Consider referral if patient requires 
step 3 care (step 2 for children 
0–4 years of age)
•	 Other conditions complicate 
asthma (e.g., sinusitis, nasal polyps, 
aspergillosis, severe rhinitis, VCD, 
GERD and COPD)
•	 Patient has required more 
than two bursts of OCS in 1 
year
•	 NR
(Continued)
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asthma, the AAAAI practice parameters document indicates 
that there is a requirement for a referral to establish the target 
allergen causing asthma by using adequate tests, such as the 
skin prick test, which require adequate training to perform 
and interpret results.29
Diagnosis of asthma or evaluation of symptoms can be 
further complicated by the presence of comorbidities, as 
they may cause respiratory symptoms.30 For instance, gas-
troesophageal reflux disease, sinusitis, allergic rhinitis and 
nasal polyposis can all result in the worsening of asthma 
symptoms31 and, therefore, may result in some diagnostic 
uncertainty. NAEPP guidelines highlight that patients with 
conditions such as sinusitis, nasal polyps, aspergillosis, severe 
rhinitis, vocal cord dysfunction, gastroesophageal reflux 
disease and chronic obstructive pulmonary disease should 
be referred to a specialist.9
Asthma severity and high-risk patients
Some patients with asthma remain uncontrolled despite 
receiving standard-of-care therapy.32 While it might seem 
appropriate that all patients with uncontrolled asthma 
should undergo specialist assessment, such a solution would 
overwhelm any health care system. Therefore, there is a 
fundamental need to select appropriate uncontrolled asthma 
patients for referral to a specialist.
A review of the guidelines in Table 1 suggests a sub-
stantial variation in recommendations for high-risk patients 
seeking a referral. Prior to a referral, primary care physicians 
(PCPs) play a pivotal role in addressing the factors behind 
poor control (e.g., poor adherence, inhaler technique and 
comorbidities).5,33 The AAAAI practice document suggests 
that all asthma patients should be considered for a referral, 
which, as highlighted previously, could result in resource 
constraints for a health care system. Several of the guidelines 
recommend that certain patients seek more specialized care 
(Table 1); for example, GINA indicates that uncontrolled 
adult patients receiving step 4 asthma therapy (moderate or 
high-dose inhaled corticosteroid [ICS]/long-acting β
2
-agonist 
or regular asthma-related health care utilization) and frequent 
exacerbators should be referred for add-on treatment, that 
is, anti-immunoglobulin E (anti-IgE) treatment or mepoli-
zumab (Table 1). In the guidelines addressing children with 
asthma, lack of control despite recommended treatment, 
usually medium- or high-dose ICS, is sufficient to seek a 
referral (Table 2). GEMA highlights that patients classified 
as having difficult-to-control asthma should be treated in a 
specialized setting.10 While the BTS guidelines do not spe-
cifically mention lack of asthma control as an indicator for a 
referral in adults, the continuation of certain symptoms and 
a biomarker (blood eosinophils) are listed as indicators for a 
Table 1 (Continued)
Situations indicated for specialist referral
Guideline Diagnostic uncertainty High-risk patients Corticosteroid treatment 
(high dose, long-term use 
and side effects)
Add-on specialist 
treatment
South African 
guidelines for the 
management of 
chronic asthma in 
adolescents and 
adults (2007)12
•	 Diagnosis is in doubt •	 Increasing severity and treatment 
(step 4–5)
•	 Poor control despite intensive 
treatment
•	 Recurrent exacerbations 
>2 per month
•	 Recent discharge following admission 
for severe exacerbation
•	 OCS dependence
•	 Significant corticosteroid 
side effects
•	 NR
Singapore Ministry 
of Health clinical 
practice guidelines 
on asthma 
management 
(2008)7
•	 Diagnosis is in doubt Adults
•	 Patients who do not achieve good 
asthma control despite step 4 level of 
treatment have refractory asthma and 
should be reviewed by a specialist
•	 Severe food allergy
•	 Refractory patients who do not have 
good asthma control despite step 4 
(medium or high-dose ICS plus one 
or more “add-on drug”)
Adults
•	 Prolonged high daily dose of 
ICS
•	 NR
Abbreviations: AAAAI, Academy of Allergy Asthma and Immunology; AIA, aspirin-induced asthma; COPD, chronic obstructive pulmonary disease; CSS, Churg Strauss 
syndrome; ED, emergency department; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GEMA, Spanish Guideline on Management of Asthma; 
GERD, gastroesophageal reflux disease; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting beta agonist; LTRA, 
leukotriene receptor antagonist; NAEPP, National Asthma Education and Prevention Program; NR, not reported; OCS, oral corticosteroid; VCD, vocal cord dysfunction.
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
27
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
215
Asthma referrals
Table 2 Guideline recommendations for referral of pediatric asthma patients to a specialist
Situations indicated for specialist referral
Guideline Diagnostic uncertainty High-risk patients Corticosteroid treatment 
(high dose, long-term use 
and side effects)
Add-on specialist 
treatment
GINA: Diagnosis and 
management of asthma 
in children 5 years or 
younger (2016)5
•	 Failure to thrive
•	 Neonatal or very early 
onset of symptoms 
(especially if associated 
with failure to thrive)
•	 Vomiting associated with 
respiratory symptoms
•	 Continuous wheezing
•	 Failure to respond 
to asthma controller 
medications
•	 No association of 
symptoms with typical 
triggers, such as viral upper 
respiratory tract infection
•	 Focal lung or 
cardiovascular signs, or 
finger clubbing
•	 Hypoxemia outside the 
context of viral illness
•	 Additional reasons 
for referral in children 
6–11 years:
•	 Doubts about diagnosis 
of asthma
•	 If symptom control remains 
poor and/or flare-ups persist 
at step 4 treatment
•	 Additional reasons for referral 
in children aged 6–11 years:
•	 Symptoms or exacerbations 
still remain uncontrolled 
despite moderate dose of 
ICS (step 4) with correct 
inhaler technique and good 
adherence
•	 If side effects of treatment are 
observed or suspected at step 
4 of treatment
•	 Additional reasons for referral 
in children aged 6–11 years:
•	 Suspected side effects of 
treatment
•	 NR
ICON on pediatric 
asthma (2012)14
•	 NR •	 Where control cannot be 
achieved with the maximum 
dose of ICS and additional 
medication, with the final 
resort being the use of OCS
•	 NR •	 NR
Diagnosis and 
treatment of asthma in 
childhood: PRACTALL 
consensus report 
(2008)13
•	 NR •	 If insufficient control after:
•	 an increase in ICS dose 
(800 μg BDP equivalent)
•	 The addition of LTRA to 
ICS or
•	 The addition of LABA after 
checking compliance
•	 Patients requiring high doses 
of ICS or doses which are not 
licensed
•	 NR
National Asthma 
Council Australia 
(2015)88
•	 Diagnostic tests (FEV1 
pre-/post-bronchodilator, 
reversible airflow 
limitation, bronchial 
provocation test and 
cardiopulmonary test) 
do not support asthma 
diagnosis
•	 Severe upper respiratory 
tract infection (severe 
rhinitis, nasal polyps)
•	 Wheezing disorder where 
asthma is not confirmed
•	 Multiple trigger wheeze
•	 Child is unable to undergo 
spirometry (<6 months 
old)
•	 Uncontrolled on ICS high 
dose OR low-dose ICS plus 
montelukast OR ICS/LABA 
(low dose) seek referral
•	 NR
(Continued)
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Table 2 (Continued)
Situations indicated for specialist referral
Guideline Diagnostic uncertainty High-risk patients Corticosteroid treatment 
(high dose, long-term use 
and side effects)
Add-on specialist 
treatment
British Thoracic 
Society (2016)8
•	 Diagnosis unclear •	 Symptoms present from birth 
or perinatal lung problem
•	 Excessive vomiting or 
posseting, severe upper 
respiratory tract infection; 
persistent wet or productive 
cough, family history of 
unusual chest disease, failure 
to thrive, nasal polyps
•	 5–12 years of age, failure 
to respond to conventional 
treatment, particularly at step 
5 (ICS up to 800 μg/day)
•	 <5 years of age, uncontrolled 
at step 3 (200–400 mg of ICS 
with LTRA)
•	 <2 years of age, uncontrolled 
at step 2 (200–400 mg ICS)
•	 Receiving high-dose ICS should 
be under specialist care
•	 Continuous or frequent use of 
oral steroids
Canadian Thoracic 
Society Guideline 
Update: Diagnosis and 
management of asthma 
in preschoolers, 
children and adults 
(2012)50
•	 NR •	 Children (6–12 years of age) 
who fail to achieve control on 
a medium dose of ICS
•	 Uncontrolled asthma in 
individuals >12 years of 
age who are on an ICS/LABA 
combination
•	 In children, the use of high 
doses of ICS due to possible 
significant side effects
•	 In all age groups, frequent 
courses of OCS should 
prompt referral to a specialist
•	 Omalizumab 
considered for 
patients >12 years 
of age with asthma 
poorly controlled 
despite high doses of 
ICS and appropriate 
add-on therapy, with 
or without OCS
Japanese guideline 
for childhood asthma 
(2014)11
•	 NR •	 Uncontrolled patients 
with step 3 (medium ICS 
dose) or step 4 (high-dose 
ICS) management strategy 
•	 NR •	 NR
South African 
guidelines for the 
management of chronic 
asthma in children 
(2009)12
•	 Diagnosis is in doubt •	 Uncontrolled asthma requiring 
level three treatment (<5 
medium dose ICS with LTRA 
or >5 medium to high-dose 
ICS/LABA)
•	 Life-threatening episode
•	 Frequent hospitalizations or 
emergency room visits
•	 High dose of ICS (>400 μg/
day)
•	 OCS required regularly
•	 Omalizumab being 
considered an option
Singapore Ministry of 
Health clinical practice 
guidelines on asthma 
management (2008)7
•	 High-risk asthma with 
poor asthma control
•	 <3 years and requires 
moderate to high doses of 
inhaled steroids and not 
responding as expected
•	 Requires high-dose steroids, 
BDP/BUD ≥400 μg/day or 
fluticasone ≥200 μg/day or is 
on prolonged inhaled steroid 
therapy for >6 months and 
remains symptomatic
•	 A severe acute asthma attack 
and requires prolonged or 
repeated OCS for control
Abbreviations: BDP, beclomethasone dipropionate; BUD, budesonide; FEV1, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; ICON, International 
Consensus; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LTRA, leukotriene receptor antagonist; NR, not reported; OCS, oral corticosteroid; PRACTALL, 
practical allergy.
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referral.8 Furthermore, both AAAAI publications on asthma 
referrals advise that patients with uncontrolled asthma should 
be referred to an immunologist/allergist (Table 1). According 
to the NAEPP and Japanese adult guidelines, patients with 
other comorbidities that could affect asthma control30 consti-
tute a high-risk group and should be referred to a specialist.
Aside from uncontrolled patients, some of the guide-
lines suggest that other patient cohorts should be referred 
to a specialist. The South African guidelines for adults and 
the AAAAI consultation and referral guideline suggest that 
severe asthma is a reason to seek a specialist referral. The 
Australian guidelines indicate that patients who have evi-
dence of poor lung function despite the use of a high dose 
of ICS for 3 months should seek a referral. GEMA recom-
mends that patients who fail to respond to treatment must 
be referred to a hospital emergency department (ED).10 In 
the case of severe asthma, guideline definitions of severe 
asthma and subsequent treatment recommendations are 
widely inconsistent because different guidelines use different 
criteria to define suboptimal asthma control.34 The differ-
ences in criteria are broadly centered on interpreting clinical 
evidence and framing recommendations. For example, there 
is a lack of clarity on whether patients should go to step 3 
or step 4 or even step 5 treatment if they are uncontrolled, 
clearly indicating that the threshold for change in treatment 
step is not clear. Currently, this threshold is so broad that 
approximately over 20% of patients receiving combination 
therapy could be referred to a specialist.35 In light of the 
significant consequences of inconsistencies among guideline 
definitions and recommendations, a common set of validated 
and clear methods across global and regional guidelines could 
harmonize treatment recommendations and enable guideline 
implementation in the management of severe asthma.
Exacerbations are known to have a huge impact on a 
patient’s quality of life,36 with asthma control and exacer-
bation history being predictors of future exacerbations.37 
Previously, it has been suggested that 20% of patients with 
asthma have had an exacerbation requiring hospitalization 
and these events can account for up to 80% of the costs asso-
ciated with asthma.38 Specialist care can reduce the number 
of hospitalizations and the risk of future hospitalizations.39 
GEMA guidelines suggest that high-risk asthma attacks or 
when severe asthma attacks occur and complications are 
suspected as a need to seek a referral to a hospital ED.10 
GINA, AAAAI and NAEPP guidelines indicate that patients 
who have frequent asthma-related health care utilization or 
a hospitalization/ED visit should be considered as high-risk 
individuals and, therefore, be referred (Table 1). The Irish 
guidelines follow this suggestion with some more specificity, 
stating that patients could be referred post-hospitalization if 
uncontrolled at step 3.6 The only other guideline with refer-
ence to an exacerbation/hospitalization as a cause for refer-
ral is the South African guideline, which recommends that 
adults who have two or more exacerbations per month are a 
group who should seek specialist care.12 The South African 
pediatric guideline is less specific in suggesting that frequent 
hospitalizations are a reason to refer (Table 2).
Furthermore, every year it is estimated that a quarter of a 
million deaths worldwide are asthma related.2 The importance 
of referrals for patients has been recently highlighted in a 
British evaluation of asthma deaths, whereby 20% of deaths 
investigated were related to avoidable factors associated with 
referrals (including delays or failure of referral for specialist 
opinion) and over 50% of patients were not under specialist 
supervision prior to their deaths.39 Of the guidelines examined 
in this review, only the GINA, NAEPP and AAAAI referral 
guidelines specifically recommend that patients who are 
at risk of an asthma-related death (GINA) or fatal asthma 
(AAAAI) or fatally prone (NAEPP) should be referred to a 
specialist (Table 1).
Use of corticosteroid treatment
Steroids play an important role in the management of asthma 
in the form of ICS and oral corticosteroids. These therapies 
have a positive impact on controlling symptoms and exac-
erbations.40 However, there are side effects associated with 
this treatment, such as growth suppression,41 hypothalamic–
pituitary–adrenal axis suppression in children,42 cataracts,43,44 
diabetes,45 and bone density changes and osteoporosis.46,47 
Similar to patients with chronic obstructive pulmonary 
disease, there is a suggestion that ICS use is associated with 
higher risk for asthma patients developing pneumonia or 
lower respiratory tract infections, particularly when used in 
high doses.48 More recently, it has been demonstrated that 
morbidity rates were increased for conditions associated with 
systemic steroid exposure in patients with severe asthma.49
Therefore, given the risks associated with this therapy, 
there is a need to monitor its use. With regard to recommen-
dations regarding the side effects in the guidelines, GINA 
suggests that any evidence or risk of side effects from treat-
ments is a reason to refer adults or children aged between 6 
and 11 years (Table 2).5 A similar statement is made by the 
AAAAI, using the example of oral corticosteroids and ICS 
in children.29 The Canadian guidelines also highlight the use 
of high-dose ICS in children and its possible side effects as 
an indication for referral (Table 2).50
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Long-term use of high doses of corticosteroids is asso-
ciated with the development of systemic side effects.49,51 
It is evident that there is a high use of ICS in asthma, and 
some of these patients are not severe enough to require this 
treatment, as observed in a British study where 90% of the 
patients were receiving ICS despite the fact that over 50% 
were classified as having intermittent asthma, and thus did 
not warrant controller therapy.52 A specialist referral could 
provide the opportunity to review the dosage of ICS pre-
scribed, and possibly to step down the dose when asthma 
control is maintained. GINA further elaborates on seeking 
a specialist referral at step 5 when there is need for add-on 
treatment, which is a preferred option to oral corticosteroids, 
if there is long-term use of oral corticosteroids or frequent use 
of oral corticosteroids (e.g., two or more courses in 1 year; 
Table 1). For children with asthma, both the South African 
and Singaporean guidelines provide more specificity on the 
doses of ICS prescribed that would justify these patients 
being referred to a specialist (Table 2). The AAAAI practice 
document states that long-term use of any medication should 
be an indication for a referral.29
PRACTALL covers the topic of prescribing unlicensed 
dose of steroids in children as a reason to seek a referral to 
a specialist (Table 2). Such use of steroids has been docu-
mented in an observational study, where ~5% of children aged 
between 5 and 11 years and 4% of children aged <5 years 
were prescribed unlicensed high doses of ICS, which could 
potentially expose these patients to treatment-related adverse 
effects.53 An examination of the Australian, BTS, Japanese 
and GINA guidelines for children ≤5 years of age reveals that 
these guidelines do not offer any recommendations on when 
to refer patients with corticosteroid use in asthma, despite 
the fact that some of the recommendations are adapted from 
guidelines that do cover this topic.
Use of add-on specialist therapies
Referring a patient to a specialist may allow them access to 
additional health care resources and add-on therapies, such 
as omalizumab, which are not available in the primary care 
setting. A recent Italian and German study highlighted that 
12% of patients who were being treated by PCPs and office-
based respiratory consultants were eligible for omalizumab, 
but were not receiving this therapy.54 Access to additional 
health care resources and treatments not available in the 
primary care setting could prevent the chronic use of oral 
corticosteroids by patients, thus reducing their exposure to 
the associated side effects of this treatment.5 This has been 
well documented with omalizumab, where a reduction in 
the use of ICS55–57 and oral corticosteroids in adults58 and 
children59 was observed. The use of this specialized add-on 
therapy has only been captured in a few guidelines. GINA 
specifically recommends asthma treatment to be on the 
basis of the level of asthma control, and it further suggests 
referring patients in step 5 (severe asthma) to a specialist, 
so that they can be assessed for additional add-on treatment, 
such as anti-IgE therapy or mepolizumab, which is preferred 
over oral corticosteroids.5 The BTS, AAAAI, Canadian, 
Japanese and South African guidelines also indicate that 
patients should be referred to a specialist if anti-IgE therapy 
is being considered. The specialist will also provide a vital 
checkpoint whereby, when required for certain patients, there 
would be an appropriate escalation to additional therapies 
such as omalizumab for severe allergic asthma patients. In 
the near future, there will be more biologics indicated for 
use in asthma, such as anti-interleukin (IL)-4/IL-13 (dupil-
umab), anti-IL13 (lebrikizumab) and new anti-IL-5 therapies 
(reslizumab and benralizumab)60 and guidelines will have 
to be updated accordingly. The use of biologics will require 
a broader diagnostic setup, potentially with biomarkers, in 
order to define eligible patients for each entity, which might 
only be available in a specialized center. This would allow 
for more personalized medicine, as well as the involvement 
of a specialist, which would ensure that they are prescribed 
to the correct patient population.
Evidence that specialist referrals are 
not occurring
Irrespective of the difference in details and information on 
specialist referral, it is evident that the asthma guidelines 
and strategy documents provide clear recommendations on 
when a referral should be sought. However, evidence sug-
gests that there is a lack of specialist referrals or a failure 
to refer in practice. As highlighted previously, an evalua-
tion of asthma deaths in the UK found that 20% of deaths 
investigated were related to avoidable factors associated with 
referrals.39 A review of asthma management in the US, based 
on NAEPP guidelines, observed that the majority of patients 
were uncontrolled and only 22% of patients had visited a 
specialist regarding their asthma care. Approximately 50% 
of patients had never visited a specialist.61 This is likely to 
be an important contributor to suboptimal management, 
given that specialist treatment can result in more favorable 
outcomes.62 It has been shown in a retrospective review of a 
pediatric asthma population that only 44% visited an asthma 
specialist within 12 months of the initial ED visit, contrary 
to guideline recommendations.63
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of decision making, coordination and access to specialty 
care.76 For example, it has been shown that patients utilized 
other hospital facilities such as ED due to a defective referral 
system.77 Specifically, the referral process has inconsistencies 
among the initiator and facilitator78 as well as the patient.79 
There could be financial disincentives to refer, especially with 
regards to physicians with ownership stakes in a practice.80 
There can also be an inadequate availability of specialists to 
provide advanced care to patients.81
What should be done in the 
specialist setting?
The benefits for patients with asthma being referred to 
specialists should result in several positive outcomes: most 
importantly, the correct identification of disease to ensure 
appropriate treatment administration as well as the main-
tenance of symptom control, and a reduction in health care 
utilization and associated costs.82
Several studies have demonstrated that when patients 
received care from an asthma specialist, the number of hospi-
talizations or the chance of these patients being hospitalized 
was reduced.62,83,84 A recent study involving children with 
moderate or severe asthma suggested that improving referral 
and attendance at asthma specialty clinics (asthma, respira-
tory or allergy clinic) for these children had the potential to 
improve clinical outcomes.63 Asthma specialists could also 
provide patients with a more enhanced education,85 which is 
an essential component of asthma management and results in 
enhanced quality of life of patients.83,85 It has been reported 
that referral to a specialist led to more effective treatment as a 
higher percentage of specialists consider pharmacotherapies 
to be essential in asthma management compared with general 
practitioners.86 Overall, specialist referral has been shown to 
be effective in improving asthma management.71
To facilitate appropriate referrals, more frequent moni-
toring should be considered for patients with moderate and 
severe persistent asthma.8 For example, in patients with an 
acute asthma attack, a respiratory specialist should follow-up 
patients admitted with a severe asthma attack for at least 1 
year after the admission. Systematic assessment of patients 
with severe asthma has increasingly been taken up by severe 
asthma clinics,87 which have expertise in diagnosis, assess-
ment of severity, comorbidities, adherence and devices, and 
individualized treatment of these patients. Guidelines and 
strategy documents5,8 now recommend that all patients with 
severe persistent asthma or a history of severe exacerbations 
requiring hospitalization be referred to an asthma specialist 
or a specialized asthma clinic.
Why are guidelines not adhered 
to and how can adherence be 
improved?
Besides documented differences in asthma guideline or 
strategy documents, the lack of knowledge on key referral 
guidelines and/or lack of implementation of these guidelines 
can ultimately impact the rate of referrals. Despite the obvi-
ous benefits of guidelines, evidence suggests that both the 
utilization of and adherence to these documents in the man-
agement of patients with asthma among HCPs are poor.64–70 A 
review of the possible reasons for poor adherence to asthma 
guideline recommendations highlighted the multifactorial 
barriers that physicians encounter, which could be grouped 
into three main areas: lack of physician knowledge about rec-
ommendations, inertia toward implementation of guidelines 
and clinical practice-related difficulties.
The lack of awareness or knowledge of guidelines by 
physicians is a barrier to physician adherence and implemen-
tation.65–70 In a study by Pinnock et al, the lack of knowledge 
of asthma guidelines among HCPs in the UK resulted in a low 
average score of 5.2 out of 11 in a web-based questionnaire 
that assessed their familiarity with guideline recommenda-
tions.65 Aside from knowledge, physicians may also disagree 
with certain guidelines and, therefore, may not follow the 
recommendations.69 Furthermore, external or practical bar-
riers (e.g., lack of time and limited staff resources) can also 
impact guideline adherence.70 It should also be noted that 
PCPs encounter patients with different asthma severities 
and control, and implementation of guideline recommenda-
tions needs to be modulated accordingly.71 Other significant 
barriers such as lack of self-efficacy and lack of belief in 
outcomes of referrals have also been noted.70
The lack of adherence to referral guidelines could be over-
come with continuing medical education and discussions with 
colleagues.72 A recent study demonstrated that a facilitator-led 
group self-assessment activity involving physicians led to 
improved quality of asthma care and adherence to guidelines.73 
Furthermore, interventions such as decision support tools, 
feedback and audit, and clinical pharmacy support could 
improve HCP adherence to asthma guidelines.74 Finally, a 
recent study by Lugtenberg et al highlighted that to implement 
guidelines, suitable and accepted interventions that are appeal-
ing to the targeted physician group need to be identified.75
It should be noted that, while guidelines and their 
implementation have an impact on referrals, there are other 
unassociated factors that can impact referrals, which have 
not been addressed in this review. The referral process, in 
general, may have breakdowns and inefficiencies in terms 
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Patients may have access to additional health care 
resources and treatments only available in the specialist 
setting, which could result in more appropriate treatment 
being administered and prevent the chronic use of oral 
corticosteroids by patients, thus reducing their exposure to 
the associated side effects of this treatment.5 Furthermore, 
referring patients with severe or uncontrolled asthma to a 
specialist also provides a vital checkpoint whereby, when 
required for certain patients, there would be an appropriate 
escalation to additional therapies, for example, omalizumab 
and mepolizumab treatment for severe allergic asthma 
patients. Such treatments are expensive and involvement of a 
specialist would ensure that they are prescribed to the correct 
patient population. Overall, regular follow-up communica-
tion between specialists and PCPs should lead to informed 
assessment of disease control, optimized treatment strategies 
and improved clinical outcomes in patients.
Conclusion
The increasing prevalence of asthma has directly increased 
morbidity, mortality and the economic burden associated 
with this disease. Despite advances in asthma therapies and 
development of several guidelines and strategy documents 
recommending referral of certain patients to a specialist 
in order to improve their asthma control and reduce health 
resources utilization, the management of asthma remains 
suboptimal. To achieve appropriate referrals, there needs 
to be additional proper dissemination, translation, train-
ing, implementation and adherence of appropriate asthma 
guidelines that suit the health care landscape. Furthermore, 
an effective specialist referral system requires better coor-
dination between health care providers and patients in 
different settings, which will allow for a better and more 
appropriate treatment for patients with asthma. The discrep-
ancy across different asthma guidelines/strategy documents 
for specialist referrals also needs to be addressed through 
development of consensus-based strategies. In particular, 
optimizing referral processes in severe asthma should be 
given priority by the health care systems in order to mini-
mize the significant morbidity and mortality associated with 
the disease. Ultimately, an improved process of specialist 
referrals would benefit patients with asthma with unmet 
needs in improving their asthma control and reducing health 
care resource utilization.
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